CardioDx, Inc. Nixes IPO, Cites Unfavorable Market Conditions
11/15/2013 10:31:01 AM
CardioDx postpones its initial public offering, citing 'unfavorable market conditions.' California molecular diagnostics company CardioDx spiked its initial public offering, citing "unfavorable market conditions," according to news reports. The 5.8-million-share offering by Palo Alto-based CardioDx was slated to raise $92 million at a share price of $14-$16 apiece. The IPO, originally scheduled for yesterday, would have seen CardioDx shares trade under the "CDX" symbol.
Help employers find you! Check out all the jobs and post your resume.
comments powered by